Description and Brand Names

Drug information provided by: Merative, Micromedex®

US Brand Name

  1. Flector
  2. Klofensaid II
  3. Licart
  4. Pennsaid
  5. Rexaphenac
  6. Solaraze
  7. Voltaren

Descriptions


Diclofenac is used to treat pain and other symptoms of arthritis of the joints (eg, osteoarthritis), such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not cure osteoarthritis and will help you only as long as you continue to use it. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID).

Diclofenac topical 3% gel is also used to treat actinic keratosis, a skin problem that may become cancerous if not treated. The exact way that topical diclofenac helps this condition is unknown.

Diclofenac topical solution is used to treat pain and swelling caused by osteoarthritis of the knees.

Diclofenac topical patch and topical system is used to treat acute pain caused by minor strains, sprains, and contusions (bruises).

This medicine is available only with your doctor's prescription.

This medicine is available without a prescription.

This product is available in the following dosage forms:

  • Patch, Extended Release
  • Solution
  • Gel/Jelly
  • Spray
  • Cream

From Mayo Clinic to your inbox

Sign up for free and stay up to date on research advancements, health tips, current health topics, and expertise on managing health. Click here for an email preview.

To provide you with the most relevant and helpful information, and understand which information is beneficial, we may combine your email and website usage information with other information we have about you. If you are a Mayo Clinic patient, this could include protected health information. If we combine this information with your protected health information, we will treat all of that information as protected health information and will only use or disclose that information as set forth in our notice of privacy practices. You may opt-out of email communications at any time by clicking on the unsubscribe link in the e-mail.

Portions of this document last updated: Nov. 01, 2023